AstraZeneca Faces FDA Setback for Breast Cancer Drug Camizestrant

AstraZeneca shares declined by 2% on Friday following a 6-3 vote by an FDA advisory panel against the approval of camizestrant, an oral drug designed to treat specific breast cancer tumors. While the FDA is not bound by its advisory committees, it typically follows their recommendations. The panel's decision centered on the results of the Phase 3 SERENA-6 clinical trial. Although the data showed a 56% reduction in the risk of disease progression or death compared to the standard of care, advisors were not convinced that switching to camizestrant early in the treatment process improved long-term survival rates for patients. Analysts from Barclays noted that the debate was nuanced, stating that the panel did not dismiss the drug's overall efficacy or safety. Instead, the committee concluded that the trial failed to prove that acting on tumor detection before radiographic progression provided a clear clinical advantage. Jefferies analysts added that the proposed shift in clinical practice was too significant for what they viewed as a modest and uncertain benefit. Despite the regulatory hurdle, the financial impact is expected to be contained. Jefferies noted that the SERENA-6 trial represents only a small portion of AstraZeneca's $80 billion sales target for 2030. The company has shown strong momentum recently, with shares rising 25% over the past year, outperforming the FTSE 100's 20% gain. AstraZeneca has stated it will continue to work with the FDA as the agency completes its formal review. The company remains in a catalyst-rich period, with 11 additional data readouts expected throughout 2026, following a first-quarter report that beat both sales and profit expectations.